Previous studies have demonstrated an inhibition of agonist-induced inositol phospholipid breakdown and intracellular Ca2+ ([Ca2+] 
INTRODUCTION
Agonist binding to platelet receptors has been shown to result in a number of biochemical changes, the earliest of these being a rapid elevation of [Ca2+] , levels and the phosphodiesterase cleavage of Ptdlns (4, 5) P2 by the enzyme phospholipase C (for reviews see [1] and [2] ). The latter reaction results in the formation of DAG and Ins(1,4,5)P3, both of which appear to play important roles in various cellular activation processes. Ins(1,4,5)P3 has been implicated in the release of Ca2+ from intracellular stores in various cells (reviewed in [3] ) including platelets [4, 5] while DAG, which activates the enzyme protein kinase C and causes the phosphorylation of a 4047 kDa protein [6] , can promote platelet secretion even at basal Ca2+ levels [7, 8] . The activation of protein kinase C by DAG can be mimicked by tumour-promoting phorbol esters such as PMA and phorbol 12,13-dibutyrate [9] , which also induce platelet secretion at basal [Ca2+]1 levels [8] , although secretion induced by all these agents can be greatly potentiated by small increases in Ca2+ [6] [7] [8] .
However, in addition to the stimulatory effects on platelets, and other cells, several workers [10] [11] [12] [13] have reported inhibitory effects of phorbol esters on various intracellular processes activated by other agonists. In platelets, it has been reported that phorbol esters can cause an inhibition ofPtdlns(4,5)P2 breakdown, phosphatidate synthesis, [Ca2+] , mobilization and granule secretion induced by agents such as thrombin, plateletactivating factor and vasopressin [14] [15] [16] [17] . During the course of a series of studies on agonist interactions and 5HT secretion, we have observed positive synergistic effects between PMA and agonists such as ADP, platelet-activating factor and the thromboxane A2 mimetic, U46619 (1la-epoxy-9a-methanoprostaglandin H2) [18] in platelets pretreated with EGTA or indomethacin, resulting in enhanced 5HT secretion in the absence ofa significant rise in [Ca2+]j or endogenous thromboxane formation [19] . As these results were clearly not in agreement with the earlier reports, we have carried out a detailed study on the effects of PMA on 5HT secretion induced by thrombin and U46619 and correlated it with its effects on Blood collection from healthy male volunteers, who had denied taking any medication for at least 10 days, preparation of platelet-rich plasma (PRP) and washed platelets, studies on dense-granule release in platelets prelabelled with [14C]5HT (57 Ci/mol; Amersham International) and measurement of TxB2 in platelet supernatants by radioimmunoassay were done as previously described [20] . The release of flTG, a platelet a-granule marker [21] , into the supernatant of stimulated platelets was measured by using radioimmunoassay kits from Amersham International.
Thrombin (4) (5) x 108/ml. Metabolism of the released arachidonate via the cyclo-oxygenase and lipoxygenase pathways was prevented in these platelets by the addition of 500 /tMphenidone [22] . 5HT studies, and expressing the released label as a percentage of the total radioactivity incorporated into the platelets. In initial experiments, these supernatants were subjected to organic extraction followed by t.l.c. of the dried extracts [23] , and these studies revealed that all the released label co-migrated with authentic arachidonic acid.
Measurement of [Ca2+11 levels
These were carried out by incubating platelets resuspended in buffer A (minus albumin) with 7 /sM-Quin 2 ester for 30 min at 37°C, in the presence of hirudin (0.05 unit/ml). Following the incubation period, centrifugation and resuspension of the platelets in buffer B (minus albumin) at a platelet count of (1.0-1.5) x 108/ml was carried out as described above for the [3H]arachidonate studies. Fluorescence measurements at 37°C were carried out with a Perkin-Elmer LS5 luminescence spectrometer, with excitation at 339 nm and emission at 500 nm. The cuvette containing the platelets was not stirred and the calculation of the [Ca2+], concentration (nM) was carried out as described previously [24] . Statistical analysis Analysis of the data was carried out by using Student's t test for unpaired data.
RESULTS

Effect of PMA on thrombin-and U46619-induced rise in
[Ca2+11 levels, arachidonate and thromboxane release and granule secretion
The effect of PMA on thrombin-and U46619-induced platelet activation depended on the particular phenomenon being examined, and on the incubation time with PMA. At least with [14C]5HT secretion, the effects obtained with incubation times of 10 s-2 min were distinct from those obtained with longer incubation times of 3-5 min; hence the effects obtained with the short and long incubation times will be dealt with separately. Preincubation of PMA for 10 s-2 min
Although initial experiments with PMA and its effect on thrombin-induced rise in [Ca2+], levels were carried out using a range of PMA concentrations between 1 and 160 nm, all subsequent experiments described in Figs. [1] [2] [3] and Tables 1 and 2 were caried out with a single fixed concentration of PMA, which was 16 fnM in washed platelets and 400 nm in PRP. These concentrations were found to be maximally effective at inducing platelet 
All experiments were carried out in washed platelets resuspended in Hepes-buffered saline (pH 7.4) containing 1 mim-Ca2+, at a platelet count of (3-5) x 108/ml. For the thrombin experiments, PMA or vehicle was added 10 s or 5 min before thrombin as indicated and, for the experiments with PMA alone, PMA was added 10 s or 5 min before vehicle, which substituted for thrombin. The values represent means+S.E.M. for data (9-12 determinations) from three similarly performed experiments, using platelets from different donors. **P < 0.002, ***P < 0.001 compared with vehicle plus thrombin. [14C]5HT secretion when added 10 s-2 min before either agonist. On the other hand, the [14C]5HT dose-response curves to thrombin and U46619 were shifted up to 4-fold to the left, depending on agonist concentration, in the presence of PMA (Figs. 2 and 3) . With subthreshold to threshold concentrations of thrombin and U46619, PMA caused a significant potentiation of agonist-induced (14C]5HT secretioni, which was significantly (P < 0.02) greater than the sum of the percentage release obtained when PMA and agonist were added alone (Figs. 2 and   3 ), e.g. PMA alone, 12% ± 4% ; 0.01 unit ofthrombin/ml alone, 6% ±4%, PMA+0.01 unit of thrombin/ml, 44 % ± 4 %, when PMA was added l0 s before thrombin (Fig. 2) . With higher concentrations of thrombin and U46619, which induced 20-50% [14C]5HT release on their own, addition of PMA 10 s-2 min before the agonist resulted in a simple additive effect of PMA and agonist on [14C]5HT secretion, e.g. PMA alone, 16% ±2%, 3 M-U46619 alone, 49 % ± 3 % ; PMA+3 M-U46619, 63 % ± 4 % (Fig. 3) , while with maximal concentrations of thrombin inducing 70-80% [14C]5HT release, no effect of PMA was observed (Fig. 2) .
The synergistic effects of agonist and PMA on [14C]5HT secretion were not significantly affected by the addition of EGTA (5 mM) or indomethacin (Fig. 2 Fig. 3 ), but the [14C]5HT curve obtained when PMA was added 10 s before U46619 in the presence of EGTA was superimposable with that obtained in the absence of EGTA.
Preincubation of PMA for 5 mi
Longer preincubations of PMA for 5 min before agonist addition resulted in more pronounced inhibitory effects on all agonist-induced phenomena.
[Ca2+], mobilization induced by all concentrations of thrombin and U46619 tested was inhibited by 80-100% (Fig. 1) and concomitant with this, thrombin-induced release of 14C]arachidonate, TxB2 and 8ITG were inhibited by 50-100% (Table 1 ). The level of [14C]5HT release in response to thrombin and U46619 was significantly (P < 0.001-0.01) less in platelets pretreated with PMA for 5 min than in platelets pretreated with PMA for 10 s-2 min. At all agonist concentrations, therefore, this was less than the sum of that obtained when PMA and agonist were added alone (Figs. 2 and 3) . At low concentrations of thrombin (< 0.02 unit/ml) and all concentrations of U46619 tested, the percentage [14C]5HT release was not significantly different (P> 0.05) from that obtained with PMA alone or agonist alone, whichever was higher, while at submaximal to maximal concentrations of thrombin (0.05-0.2 unit/ ml), a significant (P < 0.01-0.002) reduction in the percentage [14C]5HT release compared with control was observed (Fig. 2) . This reduction of thrombin-induced [14C]5HT release by PMA was specific for PMA, as addition of U46619 (0.3-1 ,M), which induced 15-20% [14C]5HT release on its own, 5 min before thrombin (0.05-0.2 unit/ml), had no similar inhibitory effect (results not shown).
Pre-incubation of 4fl-phorbol, the inactive parent compound of PMA [14] , (16- The conversion of arachidonate (500 FM) to TxB2 measured by radioimmunoassay (cross-reactivity of arachidonate with the antisera for TxB2 was less than 0.001%) in PRP was reduced by pretreatment of the platelets with PMA for 10 s or 5 min (Table 2) . A greater degree of inhibition was observed with the longer time of pretreatment, and this was statistically significant (P < 0.005) compared with the vehicle control. Interestingly, the level of [14C]5HT release induced by arachidonate was not significantly (P > 0.05) affected by a 10 s or 5 min pretreatment with PMA, although it was virtually abolished by addition of indomethacin, both in the presence and absence of PMA (Table 2) . [11, 12, 14, 15, 25] , Na+/H+ exchange transport systems [26] , inositol phospholipid synthesis [27] and breakdown [14] [15] [16] [17] , as well as effects on enzyme/receptor-regulating proteins, such as the guanine nucleotide binding proteins involved in the regulation of adenylate cyclase [28] [29] [30] . In platelets, the inhibition of agonist-induced [Ca2+], mobilization and Ptdlns(4,5)P2 breakdown by phorbol esters [14] [15] [16] [17] has led to the view that protein kinase C activation could be an important 'feed-back' regulator of these agonistinduced phenomena and, consequently, agonist-induced platelet activation, which is dependent on these processes [6] [7] [8] [9] [10] .
Our results confirm the earlier reported [14, 15] inhibition [10, [14] [15] [16] [17] breakdown [16, 32] even in our system, it seems that these effects may be too weak to inhibit platelet responses such as secretion. Thus, the physiological significance of the inhibitory effects of PMA and indeed, the role of protein kinase C activation in the termination of agonist-induced responses, at least in human platelets, need to be reconsidered.
On the other hand, it may be significant that both PMA and 1-oleoyl-2-acetylglycerol [31] were able to potentiate agonist-induced 5HT secretion in the absence of a significant rise in [Ca2+]i and endogenous thromboxane formation. Although the synergistic effects of agonist and PMA on 5HT secretion in this study are only apparent with the short preincubations with PMA (10 s-2 min), the existence of synergism even with the 5 min preincubations is implied by the finding that a 5 min preincubation with PMA totally suppressed U46619 (3 ,tM)-induced rise in [Ca2+], levels, but had no noticeable effect on 5HT secretion. However, the extent of 5HT secretion in this case was lower than that seen when PMA was added 10 s before U46619, and this is probably due to inhibitory effects of PMA counteracting the synergistic effects to some extent. It is noteworthy that, unlike 5HT secretion, no synergistic potentiation of ,8TG secretion by agonist and PMA was observed even with the short incubations with PMA, and this suggests that different mechanisms may be involved in the release of these dense-and a-granule markers. The effects of PMA on agonist-induced platelet responses seem complex and the mechanism(s) behind its inhibitory and potentiatory effects remains to be determined. The potentiatory effects of PMA on agonist-induced 5HT secretion are, however, interesting as they are shared by l-oleoyl-2-acetylglycerol and, as they occur at basal [Ca2+], levels, are unlike the synergistic effects described earlier between Ca2+ ionophores and PMA [6, 8] 
